spec sheet8 rows
TAK-071 is Takeda's M1 muscarinic positive allosteric modulator, built around a deliberately low cooperativity value on the finding that cooperativity, not potency, is what decides whether an M1 drug causes diarrhoea; it reached a phase 2 crossover trial in Parkinson disease where it missed its gait endpoint and improved a secondary cognitive measure.
- selective M1 PAM that boosts cognition by sensitizing the receptor to your own acetylcholine, not force-activating it
- low-cooperativity design widens the gap between cognitive benefit and GI side effects vs older M1 PAMs
- additive with donepezil at sub-effective doses in preclinical models
- reversed memory deficits in a Lewy body/Parkinson's dementia model and reduced falls in a Parkinson's-falls model
- reached phase 1 clinical development for cognitive impairment
- Improved a composite of attention, executive function and memory against placebo in Parkinson disease with cognitive impairment
- Wide separation between the cognitive dose and the diarrhoea dose in rodents
- No pharmacokinetic interaction with donepezil in healthy volunteers
- Reversed scopolamine-induced electroencephalogram slowing in monkeys, giving a translatable biomarker
- Gastrointestinal events accounted for the withdrawals in the phase 2 trial
- Cholinergic effects remain the class risk, and the safety margin has been measured only in rodents
- Human exposure beyond six weeks has not been studied
Overview
The most carefully engineered compound in the muscarinic field, and the clearest human test so far of the low-cooperativity idea. The phase 2 result is genuinely mixed rather than positive: the gait endpoint the trial was designed around did not move, and the cognitive signal came from a secondary outcome in 54 people. Worth watching; not yet worth believing.
- its key trick is a low 'cooperativity' number, which is what separates the cognitive benefit from the diarrhea that plagues muscarinic drugs.
- it worked together with donepezil at doses where each drug alone did nothing.
- it reduced falls in a rat model of Parkinson's, targeting a problem that dopamine drugs largely ignore.
- it sensitizes the M1 receptor to your existing acetylcholine rather than switching it on directly.
- The primary endpoint of the Parkinson trial was not a cognitive test but a gait measurement: stride time variability during a two-minute walk, taken with and without a serial subtraction task loaded on top, on the theory that falls in Parkinson disease come partly from the cholinergic side of attention rather than the dopaminergic side of movement.
- TAK-071's half-life in humans is 46 to 60 hours, long enough that once-daily dosing accumulates substantially before steady state.
Mechanism
TAK-071 is a selective positive modulator (PAM) of the M1 receptor, engineered around an unusual design principle: low cooperativity. M1 activation is a long-standing target for cognitive impairment in cholinergic-deficit disorders, but agonists and high-cooperativity PAMs cause dose-limiting gastrointestinal effects (diarrhea, cramping) through muscarinic receptors in the gut.
Takeda's work showed that lowering a PAM's cooperativity, its 'alpha-value', widens the gap between cognitive benefit and GI side effects; TAK-071 has a low alpha-value of about 199, versus 511 for the clinically tested MK-7622 and 1786 for the high-cooperativity tool T-662 (Mandai et al., 2020, Pharmacol Res Perspect, https://doi.org/10.1002/prp2.560). rather than activating M1 on its own, it sensitizes the receptor to endogenous , so the enhancement tracks physiological cholinergic tone. preclinically it reversed scopolamine-induced memory deficits at doses roughly 100-fold below those causing diarrhea, acted additively with the cholinesterase inhibitor donepezil at individually sub-effective doses, and reversed memory deficits in an A53T alpha-synuclein-overexpressing mouse model of Lewy body/Parkinson's dementia (Mandai et al., 2020). a distinctive translational finding is in Parkinson's-type falls: falls in Parkinson's are partly driven by loss of basal forebrain cholinergic neurons disrupting the attentional control of gait and balance, a problem resistant to replacement. in rats with dual cholinergic-dopaminergic lesions modeling this, TAK-071 reduced falls on rotating and zigzag rod tasks, especially under the most demanding conditions (Kucinski & Sarter, 2021, Psychopharmacology, https://doi.org/10.1007/s00213-021-05822-x).
TAK-071 advanced into phase 1 clinical testing for cognition; its human efficacy is not yet established, but it stands as a leading example of the selective, tolerability-optimized M1-PAM strategy for cognitive and gait/balance deficits.
receptor fingerprint
M1 receptor (M1 / CHRM1)positive allosteric modulator with low cooperativity (alpha-value ~199); enhances acetylcholine signaling at M1 without strong direct activation
M1 (CHRM1)Positive allosteric modulator
M2 to M5 (CHRM2 to CHRM5)Reported as potent and highly selective for M1 across the muscarinic panel
Ileal smooth muscle contractionNot augmented at concentrations that potentiate M1, unlike the high-cooperativity comparator T-662
gastrointestinal M-receptor-mediated contraction (off-target margin)low cooperativity widens the gap between cognitive benefit and GI side effects like diarrhea
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
In healthy volunteers, single doses up to 160 mg and repeat doses up to 15 mg once daily were tolerated, and the first-in-human report describes TAK-071 as largely free of cholinergic adverse effects when given without donepezil; the half-life ran 46 to 60 hours, brain penetration was good, and coadministration with donepezil changed neither drug's pharmacokinetics [6]. In the phase 2 Parkinson trial, treatment-emergent adverse events were essentially the same on drug and placebo, 19 of 53 against 18 of 49; four participants on TAK-071 withdrew for adverse events and four had gastrointestinal events [7].
Gastrointestinal effects are the signal to watch, because that is precisely the failure mode low cooperativity was designed to avoid; in rats diarrhoea appeared at 10 mg/kg against 0.3 mg/kg for the cognitive effect, a separation the high-cooperativity comparator did not have at any dose [3]. Longer-term human safety is not known, because the longest reported human exposure is six weeks [7].
History
Takeda's neuroscience unit in Fujisawa disclosed TAK-071 in 2018, after establishing that cooperativity rather than potency governs the gastrointestinal risk of M1 positive allosteric modulators [3]. A first-in-human study in healthy volunteers followed, paired with a monkey electroencephalogram biomarker programme [6] [5]. A phase 2 randomised, double-blind, placebo-controlled crossover trial in Parkinson disease with cognitive impairment and a history of falls ran from October 2020 to February 2023 at 19 sites in the United States, with the Michael J. Fox Foundation as collaborator, and reported in JAMA Neurology in 2025 [7]. A later population pharmacokinetic and exposure-response analysis placed the cognitive benefit on a plateau between 5 and 7.5 mg once daily and proposed 7.5 mg for any future study [8].
Reputation
Regarded inside the muscarinic field as the compound that turned a side effect problem into a measurable design parameter, and Takeda's own 2025 review frames low cooperativity and low intrinsic agonism as the two escape routes from cholinergic toxicity. Outside that field it is barely known. The phase 2 result reads as encouraging to anyone weighting the cognitive secondary and as a miss to anyone weighting the primary endpoint, which is a fair description of what it was.
Subjective profileweighing the evidence above
The low-cooperativity design is the interesting part; it is a serious attempt at the gastrointestinal problem that has sunk muscarinic cognition drugs for decades. It only reached Phase 1, so the striking results stay preclinical, and grey-market powder is not a way to test them.
Resources
This entry is here for reference.
Research
- 2019first citedTAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive fu…
- 2025most recentAn Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With…
- 1.T-495, a novel low cooperative M(1) receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk.
- 2.Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071.
- 3.TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects
- 4.In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents
- 5.TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys
- 6.Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects
- 7.An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial
- 8.Population Pharmacokinetic and Exposure-Response Analysis of the Cognitive Effects of TAK-071 in Participants With Parkinson Disease and Cognitive Impairment
- 9.Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia
- 10.Rescuing the attentional performance of rats with cholinergic losses by the M1 positive allosteric modulator TAK-071
- 11.M1 receptor positive allosteric modulators discovery approaches
11 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is TAK-071?
it is a positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor from Takeda. rather than switching M1 on directly, it amplifies the receptor's response to your own acetylcholine, which is a strategy for boosting cognition in conditions with cholinergic deficits (Mandai et al., 2020, Pharmacol Res Perspect, https://doi.org/10.1002/prp2.560).
why 'low cooperativity' and why does it matter?
M1 activation improves cognition but classically causes gastrointestinal side effects like diarrhea. Takeda found that a PAM with lower cooperativity (a low 'alpha-value', around 199 for TAK-071) separates the cognitive benefit from the gut side effects, giving a wider therapeutic window than high-cooperativity M1 PAMs like MK-7622 (Mandai et al., 2020, Pharmacol Res Perspect, https://doi.org/10.1002/prp2.560).
what is it developed for?
cognitive impairment tied to cholinergic dysfunction, which spans schizophrenia, Alzheimer's and Lewy body dementias, and, more unusually, the gait and balance problems of Parkinson's disease. it improved attention and, in a rat model, reduced falls linked to combined cholinergic-dopaminergic loss (Kucinski & Sarter, 2021, Psychopharmacology, https://doi.org/10.1007/s00213-021-05822-x).
does it actually help cognition?
in animals, yes. it reversed scopolamine-induced memory deficits with a wide margin against diarrhea, worked additively with donepezil at sub-effective doses, and reversed memory deficits in a mouse model of Lewy body/Parkinson's dementia (Mandai et al., 2020, Pharmacol Res Perspect, https://doi.org/10.1002/prp2.560). human efficacy is still being established; the compound reached phase 1 clinical testing.
how is it different from donepezil or other cholinergic drugs?
cholinesterase inhibitors like donepezil raise acetylcholine everywhere by blocking its breakdown, which drives dose-limiting GI effects. TAK-071 instead selectively sensitizes one receptor subtype (M1) to existing acetylcholine, aiming for cognitive benefit with fewer peripheral side effects, and it can complement donepezil rather than replace it.
the Parkinson's falls angle is unusual; what is that about?
falls in Parkinson's are partly driven by loss of forebrain cholinergic neurons disrupting the attentional control of balance, and they resist dopamine drugs. in rats with combined cholinergic-dopaminergic lesions, TAK-071 reduced falls on demanding moving-rod tasks, suggesting M1 PAMs might help the dopamine-resistant gait and balance problems of Parkinson's (Kucinski & Sarter, 2021, Psychopharmacology, https://doi.org/10.1007/s00213-021-05822-x).
can i buy it as a cholinergic nootropic?
no. it is an investigational drug in early clinical development, not a supplement, and it has no established consumer dose. it is included as a leading example of the selective M1-PAM approach to cognition.
Did TAK-071 work in Parkinson's disease?
Partly, and not on the endpoint it was built for. The phase 2 crossover trial in 54 people with Parkinson disease, cognitive impairment and at least one fall in the previous year used stride time variability during a two-minute walk as its primary outcome. After six weeks that did not differ from placebo with a cognitive load (geometric mean ratio 1.15, 95% CI 0.94 to 1.41, P = 0.16) or without one (1.02, 95% CI 0.88 to 1.18, P = 0.78). The secondary cognitive composite did improve, by a least squares mean difference of 0.22 (95% CI 0.05 to 0.38, P = 0.01). A negative primary alongside a positive secondary in 54 people is a reason to run a larger trial, not a reason to call the drug effective.
What does low cooperativity mean and why does it matter?
Cooperativity is how much an allosteric modulator multiplies the receptor's response to its natural ligand, written as an alpha value. TAK-071 sits at 199; the comparator T-662 sits at 1,786. The high number produced diarrhoea in rats at roughly the same dose that improved memory, while TAK-071 needed about thirty times more drug to cause diarrhoea than to improve cognition. Cooperativity, rather than raw potency, is the knob that separates the wanted effect from the cholinergic side effects, which is why it became the design target for this whole generation of compounds.
Can I buy TAK-071?
No. It is an investigational compound that has completed phase 1 and phase 2 studies and is not approved or sold anywhere.
How does it compare with donepezil?
The mechanisms stack rather than compete. Donepezil raises acetylcholine everywhere by blocking its breakdown; TAK-071 makes M1 respond more strongly to whatever acetylcholine is present. The two were given together in healthy volunteers with no effect on either drug's pharmacokinetics, and in rodents sub-effective doses of a low-cooperativity modulator plus a cholinesterase inhibitor improved memory when neither did alone. Worth noting that the phase 2 Parkinson trial excluded anyone taking a cholinesterase inhibitor, so the combination has not been tested for efficacy in patients.
How does this relate to older muscarinic drugs like milameline and sabcomeline?
It is the answer to why they failed. Milameline, sabcomeline and alvameline all bound the acetylcholine site itself and had to be pushed until they turned M1 on, which meant turning M2 and M3 on as well; all three ran into sweating, salivation, nausea, diarrhoea or bradycardia before reaching a convincing cognitive effect. TAK-071 and VU0486846 bind a separate site and amplify the brain's own acetylcholine rather than substituting for it, and both were tuned to amplify weakly on purpose. The same target, approached from the opposite direction.
Adverse effects
- Gastrointestinal events accounted for the withdrawals in the phase 2 trial
- Cholinergic effects remain the class risk, and the safety margin has been measured only in rodents
- Human exposure beyond six weeks has not been studied